ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Kai Ou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2762-6719; OpenAlex author ID A5022474763. Sources: OpenAlex.

Their work

Papers: 3
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 7

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 3

Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy for advanced pancreatic cancer. Co-author DOI 10.1186/s12885-025-13799-5 ↗
Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report. Co-author DOI 10.3389/fonc.2023.1151178 ↗
ALK Rearrangement-Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Report. Co-author DOI 10.3389/fonc.2021.724815 ↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Xiaoting Ma · 2 shared papers, 2023–2025 · strength 0.44
- Paper Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy … DOI 10.1186/s12885-025-13799-5 ↗
- Paper Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case r… DOI 10.3389/fonc.2023.1151178 ↗
Lin Yang · 2 shared papers, 2021–2023 · strength 0.38
- Paper Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case r… DOI 10.3389/fonc.2023.1151178 ↗
- Paper ALK Rearrangement-Positive Pancreatic Cancer with Brain Metastasis Has Remarkable Response to ALK Inhibitors: A Case Re… DOI 10.3389/fonc.2021.724815 ↗
Biyang Cao · 1 shared paper, 2025 · strength 0.22
- Paper Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy … DOI 10.1186/s12885-025-13799-5 ↗
Wen Zhang · 1 shared paper, 2025 · strength 0.22
- Paper Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy … DOI 10.1186/s12885-025-13799-5 ↗
Letian Zhang · 1 shared paper, 2025 · strength 0.22
- Paper Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy … DOI 10.1186/s12885-025-13799-5 ↗
Wenwei Yang · 1 shared paper, 2025 · strength 0.22
- Paper Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy … DOI 10.1186/s12885-025-13799-5 ↗
Lin Yang · 1 shared paper, 2025 · strength 0.22
- Paper Efficacy and safety of triplet regimen capecitabine, oxaliplatin, and irinotecan (XELOXIRI) as first-line chemotherapy … DOI 10.1186/s12885-025-13799-5 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.